Royalty Pharma plc
63.86USD
+0.1100 (+0.17%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on RPRX.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.18▲ | $1.13 | 1 | 1 |
| Next quarter | $1.52▲ | $1.49 | 0 | 1 |
| Current year | $5.32▲ | $5.23 | 1 | 1 |
| Next year | $5.81▲ | $5.59 | 2 | 0 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $1.27 | $1.32 | +0.05 (+3.9%) |
| 2026-03-31 | $1.18 | $1.3 | +0.11 (+9.4%) |
| 2025-12-31 | $1.33 | $1.47 | +0.13 (+10.0%) |
| 2025-09-30 | $1.04 | $1.17 | +0.13 (+12.5%) |
49 ratings from 11 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Overweight | $65 $67 | Oct 7, 2026 |
| TD Cowen | Maintained | Buy | $65 $68 | Sep 8, 2026 |
| JP Morgan | Maintained | Overweight | $58 $62 | Aug 7, 2026 |
| TD Cowen | Maintained | Buy | $50 $65 | Jul 13, 2026 |
| Citigroup | Maintained | Buy | $50 $66 | May 7, 2026 |
| JP Morgan | Maintained | Overweight | $50 $58 | May 7, 2026 |
| UBS | Maintained | Buy | $51 $57 | Apr 21, 2026 |
| Morgan Stanley | Maintained | Overweight | $61 $63 | Apr 10, 2026 |
| UBS | Upgraded from Neutral | Buy | $38 $49 | Jan 30, 2026 |
| Citigroup | Maintained | Buy | $48 $50 | Jan 27, 2026 |
| TD Cowen | Maintained | Buy | $42 $45 | Dec 11, 2025 |
| Morgan Stanley | Maintained | Overweight | $55 $54 | Oct 10, 2025 |
| Goldman Sachs | Initiated | Buy | $42 | Sep 30, 2025 |
| Citigroup | Maintained | Buy | $40 $42 | Jul 22, 2025 |
| Morgan Stanley | Maintained | Overweight | $51 $54 | Jul 10, 2025 |
| Citigroup | Maintained | Buy | $60 $40 | Oct 25, 2024 |
| Goldman Sachs | Maintained | Buy | $50 $51 | Aug 14, 2024 |
| Morgan Stanley | Maintained | Overweight | $48 $51 | Jul 11, 2024 |
| UBS | Downgraded from Buy | Neutral | $28 | Jun 3, 2024 |
| B of A Securities | Maintained | Buy | $40 $38 | Apr 12, 2024 |
| JP Morgan | Maintained | Overweight | $45 $42 | Feb 20, 2024 |
| Goldman Sachs | Maintained | Buy | $56 $50 | Feb 20, 2024 |
| Morgan Stanley | Maintained | Overweight | $54 $57 | Nov 9, 2023 |
| Morgan Stanley | Maintained | Overweight | $53 $54 | Oct 11, 2023 |
| Morgan Stanley | Maintained | Overweight | $52 $53 | Aug 9, 2023 |
103 filings from 18 insiders · 19 buy / 14 sell over 6m
Officers and directors of RPRX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Urist MarshallOfficer, EVP, Research & Investments | Sell | 4.1k | $57.10 | $236k | Oct 5, 2026 |
| Bassler Bonnie LDirector | Grant | 642 | $58.41 | $37k | Sep 30, 2026 |
| Urist MarshallOfficer, EVP, Research & Investments | Sell | 4.1k | $57.88 | $239k | Sep 28, 2026 |
| Hite ChristopherOfficer, EVP & Chairman, Partnering | Sellindirect | 3.9k | $58.93 | $231k | Sep 22, 2026 |
| Hite ChristopherOfficer, EVP & Chairman, Partnering | Sellindirect | 96.1k | $58.51 | $5.62M | Sep 22, 2026 |
| HITE CHRISTOPHEROfficer | Gift | 16.8k | — | — | Aug 19, 2026 |
| HITE CHRISTOPHEROfficer | Sellindirect | 100.0k | $59.97 | $6.00M | Aug 18, 2026 |
| COYNE TERRANCE PChief Financial Officer | Sellindirect | 11.0k | $58.59 | $646k | Aug 13, 2026 |
| HITE CHRISTOPHEROfficer | Grantindirect | 11.0k | — | — | Aug 5, 2026 |
| COYNE TERRANCE PChief Financial Officer | Grantindirect | 11.0k | — | — | Aug 5, 2026 |
| URIST MARSHALL J.Officer | Grant | 8.3k | — | — | Aug 5, 2026 |
| LEGORRETA PABLO GChief Executive Officer | Grant | 65.2k | — | — | Aug 5, 2026 |
| URIST MARSHALL J.Officer | Sell | 9.1k | $55.88 | $508k | Jul 1, 2026 |
| HITE CHRISTOPHEROfficer | Sell | 130.0k | $56.44 | $7.35M | Jun 30, 2026 |
| BASSLER BONNIE LDirector | Grant | 689 | $54.40 | $37k | Jun 30, 2026 |
| URIST MARSHALL J.Officer | Sell | 9.1k | $55.18 | $502k | Jun 24, 2026 |
| HITE CHRISTOPHEROfficer | Sellindirect | 150.0k | $54.11 | $8.16M | Jun 23, 2026 |
| ENGELBERT CATHERINE M.Director | Grant | 4.5k | — | — | Jun 5, 2026 |
| NORDEN GREGORYDirector | Grant | 4.5k | — | — | Jun 5, 2026 |
| BASSLER BONNIE LDirector | Grant | 4.5k | — | — | Jun 5, 2026 |
No analyst notes on RPRX yet.
Analyst Ratings
8 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 5 | 1 | 0 | 0 | Buy1.88 |
| 1 mo ago | 2 | 5 | 1 | 0 | 0 | Buy1.88 |
| 2 mo ago | 2 | 5 | 1 | 0 | 0 | Buy1.88 |
| 3 mo ago | 2 | 6 | 2 | 0 | 0 | Buy2.00 |
Members whose judged calls on RPRX have played out most reliably.
No settled calls on RPRX yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice